- |||||||||| Trial completion, Enrollment change, Trial primary completion date: PseudIgY: Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis (clinicaltrials.gov) - Sep 2, 2016
P1/2, N=14, Completed, Enrolling by invitation --> Completed | N=200 --> 114 | Trial primary completion date: Dec 2016 --> Sep 2016 Active, not recruiting --> Completed | N=20 --> 14 | Trial primary completion date: Dec 2018 --> Dec 2012
- |||||||||| Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Trial primary completion date: Efficacy of Rifaximin in Preventing Campylobacteriosis (clinicaltrials.gov) - Sep 1, 2016 P2/3, N=28, Active, not recruiting, Active, not recruiting --> Completed | N=20 --> 14 | Trial primary completion date: Dec 2018 --> Dec 2012 Trial primary completion date: Jun 2016 --> Dec 2016
- |||||||||| Trial completion, Enrollment change: Gastric and Duodenal Microbiota in Dyspeptic Subjects (clinicaltrials.gov) - Aug 31, 2016
P=N/A, N=121, Completed, Recruiting --> Active, not recruiting | Phase classification: P2 --> P2a Recruiting --> Completed | N=200 --> 121
- |||||||||| Shanchol (oral cholera vaccine) / Sanofi
Trial primary completion date: ICVB: Introduction of Cholera Vaccine in Bangladesh (clinicaltrials.gov) - Aug 31, 2016 P=N/A, N=240000, Recruiting, Recruiting --> Completed | N=200 --> 121 Trial primary completion date: Dec 2015 --> Dec 2016
- |||||||||| Trial completion, Enrollment change: Validity of Patient-Collected Wet Mounts (clinicaltrials.gov) - Aug 26, 2016
P=N/A, N=77, Completed, Trial primary completion date: Jun 2016 --> Oct 2016 Recruiting --> Completed | N=40 --> 77
- |||||||||| rifampicin / Generic mfg.
Trial completion, Trial primary completion date: Trial of High-Dose Rifampin in Patients With TB (clinicaltrials.gov) - Aug 19, 2016 P2, N=180, Completed, Trial primary completion date: Apr 2017 --> Aug 2017 Active, not recruiting --> Completed | Trial primary completion date: Apr 2015 --> Apr 2016
- |||||||||| Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis (clinicaltrials.gov) - Aug 19, 2016
P=N/A, N=19, Completed, Active, not recruiting --> Completed | Trial primary completion date: Apr 2015 --> Apr 2016 Recruiting --> Completed | N=25 --> 19 | Initiation date: Jun 2015 --> Sep 2015 | Trial primary completion date: May 2016 --> Dec 2015
- |||||||||| Enrollment closed, Enrollment change, Trial initiation date, Trial primary completion date, Adherence: Improved Adherence to C. Difficile Isolation Protocols Through Improved Education Methods (clinicaltrials.gov) - Aug 12, 2016
P=N/A, N=38, Active, not recruiting, Recruiting --> Completed | N=1500 --> 1997 | Trial primary completion date: Jun 2015 --> Sep 2015 Not yet recruiting --> Active, not recruiting | N=600 --> 38 | Initiation date: May 2016 --> Jan 2015 | Trial primary completion date: Jan 2017 --> Jan 2016
|